Small molecule · Inhibitor of leucine-rich repeat kinase 2 (LRRK2) · developed by Neuron23
Phase 2Most advanced trial
1Registered trials
What is NEU-411?
NEU-411 is an orally bioavailable, brain-penetrant small molecule that selectively inhibits LRRK2 kinase activity. It is being studied in Parkinson disease, including early Parkinson disease.
Summary written with AI from the sources listed at the end of this page.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.